Zydus Lifesciences Launches India's First Trivalent Influenza Vaccine 'VaxiFlu™' Aligning with Global WHO Recommendations

Zydus Lifesciences Ltd., a global innovation-led healthcare company, announced the launch of its trivalent influenza (Flu) vaccine 'VaxiFlu™' in India. This is the first trivalent influenza vaccine in the country, aligning with the global recommendations of the World Health Organization (WHO). The vaccine is introduced in response to the global health concern of seasonal influenza, which causes 3-5 million cases of severe illness and 290,000 to 650,000 respiratory deaths annually. The trivalent vaccine is recommended by WHO, CDC, and the National Centre for Disease Control (NCDC), Government of India for the 2025-2026 northern hemisphere influenza season. VaxiFlu™ is recommended for individuals aged 6 months and above and contains the latest, updated strains selected based on WHO’s annual surveillance and recommendations.